Sydnexis

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Sydnexis sits in the upper half of US sponsors by registered trial count (#7,390 of 15,751 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed later-stage tilt upper half by trial count

Sydnexis: 1 sponsored US clinical trial, none currently recruiting.

Sydnexis sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Near Sightedness, with 1 trials.

Mid-pack sponsor footprint

Sydnexis is in the upper half of sponsors by trial count (#7,390 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 3 1

Therapeutic Areas

How the Sydnexis archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Near Sightedness (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nationwide sponsors with similar pipelines

Cross-sponsor peers matched on registered trial volume and open-enrollment share, not the same therapeutic-area sidebar.

Similar trial volume (± open share)

Similar open-enrollment share (± trial volume)

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.